Back to Newsroom

Alder BioPharmaceuticals Appoints Nancy L. Boman, M.D., Ph.D., Senior Vice President of Regulatory Affairs and Pharmacovigilance

BOTHELL, Wash., Sept. 21, 2016 (GLOBE NEWSWIRE) — Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced the appointment of Nancy L. Boman, M.D., Ph.D. as senior vice president of regulatory affairs and pharmacovigilance. Dr. Boman will be responsible for developing and implementing the regulatory strategy and pharmacovigilance program of ALD403 for migraine prevention as it advances through pivotal trials and toward a planned Biologic License Application (BLA) with the U.S. Food and Drug Administration (FDA).

Click here to read the full release